RCT: Long-term efficacy and safety of up to 108 weeks of Ixekizumab in pediatric patients with moderate to severe plaque psoriasis.

Long-term Efficacy and Safety of Up to 108 Weeks of Ixekizumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis: The IXORA-PEDS Randomized Clinical Trial – JAMA Dermatology

Original Study: Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS) – British Journal of Dermatology

Commentary on Twitter

In this RCT, by 108 weeks of use of ixekizumab for pediatric psoriasis, PASI 75/90/100 were achieved in 92%/79%/55%, respectively, of children, with clearance of nails in 68%, scalp in 76%, genital lesions in 88%, and palm/sole involvement in 90%. https://t.co/vk73Z3MKi4

— JAMA Dermatology (@JAMADerm) April 13, 2022